<DOC>
	<DOC>NCT02202395</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy and safety of Hydroxytriptolide(LTS) in active rheumatoid arthritis patients with an inadequate response to methotrexate.</brief_summary>
	<brief_title>Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate</brief_title>
	<detailed_description>1. Investigate the efficacy of Hydroxytriptolide in active RA patients 2. Investigate the safety of Hydroxytriptolide in active RA patients. Especially in female reproductive system. 3. Population PK study.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>3565 years old, female, postmenopausal, parous, nulliparous with no fertility requirements 1987 ACR Diagnostic criteria or 2009 ACR/EULAR Diagnostic criteria. X ray of Evaluable Joint in phase I/II/III, Joint Function in Phase I/II/III Active RA Continuously taking MTX for at least three months, ≥7.5mg/week. Before first study dose, keep in stable MTX dose for at least 4 weeks Keep in stable NSAIDs dose or lowdose glucocorticoids for at least 4 weeks before first study dose Using nonprohibited combination therapy, keep in stable dose for at least 7 days before first study dose Using DMARD should have appropriate withdrawal period: Withdrawal for 4 weeks: Sulfasalazine, Azathioprine, Chloroquine, *Hydroxychloroquine, Auranofin, Penicillamine, Traditional Chinese medicine preparation(TGP, Sinomenine) Withdrawal for 8 weeks: Leflunomide Withdrawal for 8 weeks: Intramuscular, intravenous, intraarticular injection glucocorticoids Women with fertility, negative in pregnancy test, and agreed to take contraceptive measures physical Voluntary informed consent Willing to follow the required regimen and schedule, followup examination 1. Currently suffering or have suffered from other inflammatory joint diseases, such as mixed connective tissue disease, scleroderma, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, bone arthritis, rheumatoid arthritis, gouty arthritis, diagnosis of arthritis before 16yrs 2. With severe nonarticular manifestations such as high fever, interstitial pneumonia, pleurisy, pericarditis, severe vasculitis, neuropathy, etc. 3. The evaluable joint underwent the surgical treatment within 2 months 4. Currently or recent have serious, or progression, or disease history not controled, including: liver, kidney, blood, gastrointestinal, endocrine, metabolic, respiratory, cardiovascular, nervous system diseases 5. Currently or have malignancy, lymphoproliferative disease history 6. Continuously use Tripterygium preparations for more than three months and have no effect 7. History of using TNFa inhibitors of biological agents.(Adalimumab, infliximab, etanercept) 8. Severe or persistent infection within 3 months 9. Xray shows active pulmonary infection 10. HBV, HCV, HIV, AIDS 11. WBC&lt;4.0×10^9/L, PLT&lt;100×10^9/L, Hb&lt;85g/L 12. AST&gt;2×ULN, ALT&gt;2×ULN 13. Cr&gt;135umol/L 14. Used oral contraceptive druds within 3 months 15. Pregnancy test was positive or lactating patients or patients with birth preparation 16. Have to use the prohibited drugs 17. With clinical symptoms of a serious history of drug abuse or alcohol abuse 18. History of any durg clinical trials within 3 months 19. Allergy to tripterygium 20. Other reasons depends by the investigator</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hydroxytriptolide</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>T8</keyword>
	<keyword>LTS</keyword>
</DOC>